Liver Stage Plasmodium Polypeptides for Malaria Vaccine and Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective vaccines and diagnostic markers for malaria, particularly targeting the liver stage of Plasmodium parasites, which is crucial for immune response and early diagnosis.
Innovation Solution
Isolation and use of specific liver stage Plasmodium polypeptides and nucleic acid molecules, including recombinant and synthetic forms, to induce immune responses and develop immunogenic compositions for vaccine and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver stage Plasmodium polypeptides are used as vaccine candidates, then protective immune responses are elicited, but the complexity of identifying and characterizing these specific antigens increases
Solution Approach 1:
The patent segments the Plasmodium parasite into specific liver stage antigens (polypeptides) that are uniquely expressed during this stage. By isolating and characterizing specific proteins such as Plasmodium liver stage antigen 1 (PLS1) and other stage-specific proteins, the invention divides the complex parasite into manageable immunogenic components that can be individually studied and utilized in vaccines.
Solution Approach 2:
The patent performs preliminary identification and characterization of liver stage-specific polypeptides before vaccine development. Through genomic analysis, protein expression studies, and immunogenicity testing, the invention pre-identifies candidate antigens that are uniquely expressed in the liver stage, allowing for targeted vaccine design rather than using whole parasite or blood stage antigens.
2Measurement precision
If liver stage-specific molecules are identified for diagnosis, then early stage malaria detection is enabled, but the difficulty of detecting and measuring these molecules increases
Solution Approach 1:
The patent extracts and isolates liver stage-specific polypeptides from the complex Plasmodium parasite. By identifying and purifying these stage-specific molecules (such as PLS1, PLS2, and other liver-stage expressed proteins), the invention creates diagnostic targets that are uniquely present during the liver stage, enabling early detection before blood stage infection occurs.
Solution Approach 2:
The patent uses liver stage polypeptides as intermediary markers that bridge the gap between infection and detectable disease. These polypeptides serve as detectable proxies for the invisible liver stage parasites, allowing indirect detection of malaria infection through antibody or antigen detection assays against these specific molecules.
3Reliability
If recombinant and synthetic polypeptides are used for vaccine development, then immunogenicity is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent creates recombinant copies of liver stage polypeptides using genetic engineering techniques. By cloning the genes encoding these proteins into expression systems (such as bacteria, yeast, or cell lines), the invention produces synthetic copies of the native polypeptides that maintain their immunogenicity while enabling controlled manufacturing and purification.
Solution Approach 2:
The patent modifies and optimizes parameters during polypeptide production to ensure manufacturing precision. This includes optimizing expression conditions, purification protocols, and protein folding parameters to produce recombinant polypeptides that accurately reflect the native liver stage antigens in terms of structure, stability, and immunogenicity.
Data Source
AI summary
The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.